Summary
Nine patients with a recurrent malignant glioma were treated with repeated intracavitary or intracerebroventricular injections of human recombinant interleukin-2 (rIL-2) alone or in combination with systemic interferon-α (IFN-α). Five patients received only rIL-2 and four were treated with rIL-2 plus subcutaneous injections of IFN-α. Therapy was administered on a Monday, Wednesday, Friday schedule for up to 10 weeks, beginning with a dose of 10,000 IU rIL-2/injection. Doses were escalated every two weeks until some toxicity was apparent. The maximum amount of rIL-2 any one patient in this group received was 580,000 IU. Patients on combination immunotherapy were held at an rIL-2 dosage of 10,000 IU while IFN-α, which began at 3 million IU, was escalated every other week up to 18 million IU/dose. They were then held at that IFN-α dosage and rIL-2 was increased to 50,000 IU. The total amount of rIL-2 and IFN-α any one in this group received was 510,000IU and 417 million IU, respectively. Repeated injections of 10,000 IU rIL-2 were well-tolerated by all nine patients and no change in their functional status was seen. At doses at 50,000 IU. rIL-2, increased edema around the tumor cavity was observed by MRI/CT scand in 3/5 patients and clinical side-effects in the form of somnolence and headache along with some morbidity specifically associated with tumor location were also seen. Patients receiving rIL-2 + IFN-α showed progressive fatigue, muscle weakness, and occasionally nausea. Two of these patients showed increased peritumoral edema on MRI/CT scan. Neither hematological abnormalities nor changes from baseline values were seen in blood samples from any of the patients. MRI/CT scans made at the conclusion of immunotherapy indicated tumor progression in two of the patients treated with rIL-2 alone while no tumor growth at the site of treatment occurred in the other two or in the four treated with the combination of rIL-2 and IFN-α. Further clinical testing of rIL-2 in combination with IFN-α is indicated.
References
Merchant RE, Grant AJ, Merchant LH, Young HF: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62: 665–671, 1988
Merchant RE, Merchant LH, Cook SHS, McVicar DW, Young HF: Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23:725–732,1988
Atkinson LL, Merchant RE, Ghatak NR, Young HF: Sterile abscess in glioma patients treated by intraparenchymal injection of lymphokine-activated killer (LAK) cells and recombinant interleukin-2. Neurosurgery 25: 805–810,1989
Merchant RE, Ellison MD, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neuro-Oncol 8: 173–1988,1990
Mahaley MS, Urso MB, Whaley RA, Blue M, Williams TE, Guaspari A, Selker RG: Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63:719–725,1985
Nagai M: Clinical use of interferons in the treatment of malignant brain tumors. Dev Med Virol 4: 183–194, 1988
Otsuka S, Yamashita J, Keyaki A, Handa H: Recombinant Interferon-alpha A (Ro 22–8181) therapy for patients with malignant brain tumors. Gan To Kagaku Ryoho 11: 1084–1091, 1984
Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T: Effect of human leukocyte interferon on malignant brain tumors. Cancer 51: 1976–1981, 1983
Ridley A, Cavanaugh JB: Lymphocytic infiltration in gliomas: Evidence of possible host resistance. Brain 94: 117–124, 1971
Morantz RA, Wood GW, Foster M, Clark M, Gollahon K: Macrophages in experimental and human brain tumors. Part 2. Studies of the macrophage content of human brain tumors. J Neurosurg 50: 305–311, 1979
Brooks WH, Markesbery WR, Gupta GD, Roszman TL: Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 4: 219–224, 1978
Palma L, DiLorenzo N, Guidetti B: Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg 49: 854–861, 1978
Young HF, Merchant RE, Apuzzo MLJ: Immunocompetence of patients with malignant glioma. In: Salcman M (ed) Neurobiology of Brain Tumors. Baltimore: Williams and Wilkins, 1991, pp 211–227.
Mahaley MS, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S: Depressed cell-mediated immunity in patients with primary intracranial tumors. Part 1: Studies of the cellular and humoral immune competence of brain-tumor patients. J Neurosurg 46: 467–476, 1977
Roszman TL, Brooks WH: Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 39: 395–402, 1980
Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6: 1633–1636,1987
Yoshida S, Takai N, Tanaka R: Functional analysis of interleukin-2 in immune surveillance against brain tumors. Neurosurgery 21:627–630,1987
Fontana A, Hengartner H, de Tribolet N, Weber E: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132: 1837–1844, 1984
Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Internal Med 107: 293–300, 1987
Watts RG, Wright JL, Atkinson LL, Merchant RE: Histopathologic and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin-2. Neurosurgery 49: 202–208, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Merchant, R.E., McVicar, D.W., Merchant, L.H. et al. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a phase I clinical trial. J Neuro-Oncol 12, 75–83 (1992). https://doi.org/10.1007/BF00172459
Issue Date:
DOI: https://doi.org/10.1007/BF00172459